Search Results - Andrew Albright

  • Showing 1 - 17 results of 17
Refine Results
  1. 1
    Annexin 2: a Novel Human Immunodeficiency Virus Type 1 Gag Binding Protein Involved in Replication in Monocyte-Derived Macrophages

    Annexin 2: a Novel Human Immunodeficiency Virus Type 1 Gag Binding Protein Involved in Replication in Monocyte-Derived Macrophages by Elena Ryzhova, Robin M. Vos, Andrew Albright, Alexia Harrist, Thomas S. Harvey, Francisco González‐Scarano

    Published 2006
    Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism

    Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism by Julie Strizki, Andrew Albright, Hong Sheng, Matthew J. O’Connor, Lionel Perrin, Francisco González‐Scarano

    Published 1996
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples

    Pre-Analytical Considerations for Successful Next-Generation Sequencing (NGS): Challenges and Opportunities for Formalin-Fixed and Paraffin-Embedded Tumor Tissue (FFPE) Samples by Gladys Arreaza, Ping Qiu, Ling Pang, Andrew Albright, Lewis Z. Hong, Matthew J. Marton, Diane Levitan

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Chemokine Receptor Utilization by Human Immunodeficiency Virus Type 1 Isolates That Replicate in Microglia

    Chemokine Receptor Utilization by Human Immunodeficiency Virus Type 1 Isolates That Replicate in Microglia by Joseph T.C. Shieh, Andrew Albright, Matthew Sharron, Suzanne Gartner, Julie Strizki, Robert W. Doms, Francisco González‐Scarano

    Published 1998
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox

    The development and approval of tecoviromat (TPOXX®), the first antiviral against smallpox by Michael Merchlinsky, Andrew Albright, Victoria A. Olson, Helen Schiltz, Tyler G. Merkeley, Claiborne Hughes, Brett W. Petersen, M D Challberg

    Published 2019
    Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Interaction of the Human Immunodeficiency Virus Type 1 Vpr Protein with the Nuclear Pore Complex

    Interaction of the Human Immunodeficiency Virus Type 1 Vpr Protein with the Nuclear Pore Complex by Ron A. M. Fouchier, Barbara E. Meyer, James H. M. Simon, Utz Fischer, Andrew Albright, Francisco González‐Scarano, Michael H. Malim

    Published 1998
    Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Microglia Express CCR5, CXCR4, and CCR3, but of These, CCR5 Is the Principal Coreceptor for Human Immunodeficiency Virus Type 1 Dementia Isolates

    Microglia Express CCR5, CXCR4, and CCR3, but of These, CCR5 Is the Principal Coreceptor for Human Immunodeficiency Virus Type 1 Dementia Isolates by Andrew Albright, Joseph T.C. Shieh, Takayuki Itoh, Benhur Lee, David Pleasure, Michael J. O’Connor, Robert W. Doms, Francisco González‐Scarano

    Published 1999
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

    Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors by Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Lei Xu, Xiao Qiao Liu, Andrey Loboda, Lixin Lang, Fan Jin, Eric H. Rubin, Alexandra Snyder, Jared Lunceford

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

    IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade by Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, Jonathan D. Cheng, Shijun Kang, Veena Shankaran, Sarina A. Piha‐Paul, Jennifer H. Yearley, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types

    Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types by Rǎzvan Cristescu, Michael Nebozhyn, Chunsheng Zhang, Andrew Albright, Julie Kobie, Lingkang Huang, Qing Zhao, Anran Wang, Hua Ma, Zheng Cao, Michael Morrissey, Antoni Ribas, Petros Grivas, David W. Cescon, Terrill K. McClanahan, Alexandra Snyder, Mark Ayers, Jared Lunceford, Andrey Loboda

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials

    Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials by Roy S. Herbst, G. Lopes, D.M. Kowalski, Mizuho Nishio, Yechen Wu, Gilberto de Castro, Paul Baas, D.-W. Kim, Matthew A. Gubens, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Mark Ayers, Andrey Loboda, Jared Lunceford, Julie Kobie, Gregory M. Lubiniecki, Maria C. Pietanza, Bilal Piperdi, Tony Mok

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407

    Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 by Luis Paz‐Ares, Corey J. Langer, Silvia Novello, Balázs Halmos, Ying Cheng, Shirish M. Gadgeel, Rina Hui, Shunichi Sugawara, Hossein Borghaei, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Andrey Loboda, Julie Kobie, Jared Lunceford, Mark Ayers, Gregory M. Lubiniecki, M. Catherine Pietanza, Bilal Piperdi, Marina Chiara Garassino

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC

    OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC by Marina Chiara Garassino, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, Emilio Esteban, Enriqueta Felip, G. Speranza, Martin Reck, Rina Hui, Michael Boyer, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Andrey Loboda, Julie Kobie, Jared Lunceford, Mark Ayers, Gregory M. Lubiniecki, Bilal Piperdi, M. Catherine Pietanza, Edward B. Garon

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma

    Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma by Robert I. Haddad, Tanguy Y. Seiwert, Laura Q.M. Chow, Shilpa Gupta, Jared Weiss, Iris Gluck, Joseph P. Eder, Barbara Burtness, Makoto Tahara, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Andrew Albright, Robin Mogg, Mark Ayers, Lingkang Huang, Jared Lunceford, Rǎzvan Cristescu, Jonathan D. Cheng, Ranee Mehra

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC

    OA04.05 KEYNOTE-021: TMB and Outcomes for Carboplatin and Pemetrexed With or Without Pembrolizumab for Nonsquamous NSCLC by Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei, Amita Patnaik, Steven Powell, Ryan D. Gentzler, James Chih‐Hsin Yang, Matthew A. Gubens, Lecia V. Sequist, Mark M. Awad, Rǎzvan Cristescu, Deepti Aurora-Garg, Andrew Albright, Andrey Loboda, Julie Kobie, Jared Lunceford, Mark Ayers, Gregory M. Lubiniecki, Bilal Piperdi, M. Catherine Pietanza, Vassiliki A. Papadimitrakopoulou

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Biomarkers predictive of response to pembrolizumab in head and neck cancer

    Biomarkers predictive of response to pembrolizumab in head and neck cancer by David G. Pfister, Robert I. Haddad, Francis P. Worden, Jared Weiss, Ranee Mehra, Laura Q.M. Chow, Stephen V. Liu, Hyunseok Kang, Nabil F. Saba, Lori J. Wirth, Ammar Sukari, Erminia Massarelli, Mark Ayers, Andrew Albright, Andrea L. Webber, Robin Mogg, Jared Lunceford, Lingkang Huang, Rǎzvan Cristescu, Jonathan D. Cheng, Tanguy Y. Seiwert, Joshua Bauml

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy

    Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy by Rǎzvan Cristescu, Robin Mogg, Mark Ayers, Andrew Albright, Erin Murphy, Jennifer H. Yearley, Xinwei Sher, Xiao Qiao Liu, Hongchao Lu, Michael Nebozhyn, Chunsheng Zhang, Jared Lunceford, Andrew K. Joe, Jonathan D. Cheng, Andrea L. Webber, Nageatte Ibrahim, Elizabeth R. Plimack, Patrick A. Ott, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan, Joanne E. Tomassini, Andrey Loboda, David R. Kaufman

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: